BTA 243

Drug Profile

BTA 243

Alternative Names: CL 316243

Latest Information Update: 21 Mar 2002

Price : $50

At a glance

  • Originator Wyeth
  • Class Benzene derivatives; Dicarboxylic acids
  • Mechanism of Action Beta 3 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Overactive bladder; Type 2 diabetes mellitus

Most Recent Events

  • 21 Mar 2002 Discontinued - Preclinical for Overactive bladder in USA (unspecified route)
  • 20 Mar 2002 American Home Products and its subsidiary Wyeth-Ayerst are both now called Wyeth
  • 05 Oct 2001 A preclinical study has been added to the Genitourinary Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top